Here’s why that shift matters. Institutions don’t move on vibes. They move on records. A hospital dataset can drive public-health policy. A court opinion can quietly dismantle the old assumption that weed means danger. A few hundred disputed signatures can decide whether an entire legal market survives.

And right now there are two records being built at the same time, pulling in opposite directions. One treats cannabis as medicine, commerce, and pretty ordinary adult behavior. The other is scrambling to reframe it as a threat to hospitals, kids, public safety, and now, I kid you not, national security. That’s the evidence war. Whoever builds the more credible record wins the next decade. Let me walk you through the week.

Congress wants ER drug data, and the definitions are going to matter a lot.

A House committee advanced Tyler’s Law, which would require federal health officials to look at how often emergency rooms test overdose patients for marijuana, fentanyl, and other drugs. The bill is really about fentanyl. It’s named for Tyler Shamash, a 19-year-old who died after hospital staff reportedly didn’t test for fentanyl when he came in with a suspected overdose. Hard to argue with the intent there.

Better overdose data is genuinely good. Doctors should know what’s in someone’s system, especially when dangerous combinations are involved. So no complaints about the goal.

Here’s where I’d pump the brakes, though. A positive THC test tells you almost nothing about whether cannabis had anything to do with the emergency. Weed metabolites hang around for weeks after the high is long gone. So if someone comes into the ER for something completely unrelated, tests positive for cannabis they used two weekends ago, and that gets logged as a “marijuana-related” hospital visit, you’ve just manufactured a misleading statistic. And there’s already a separate Senate proposal to track Medicaid spending on marijuana-related hospital care, so these numbers are going to start driving real policy.

That’s the whole ballgame with data like this. Collected carefully, it helps. Collected sloppily, it becomes ammunition. If a positive test during an unrelated visit counts as a cannabis hospitalization, the stats will get inflated fast, and those inflated numbers will show up in the next round of prohibitionist talking points.

The bottom line: Everyone wants better ER data. But a positive weed test isn’t proof cannabis caused anything, and if the definitions are loose, the numbers will get weaponized.

Subscribe now

Minnesota has stopped asking if psychedelic therapy is legit and started asking how to run it

Minnesota is laying the groundwork for a regulated psilocybin therapy program, with supporters hoping for authorization in 2027. Lawmakers didn’t approve full access this year, but they told the Office of Cannabis Management to deliver a feasibility study and legislative report by January 2027. The state’s had a Psychedelic Medicine Task Force since 2023, and it’s already produced a big policy guide, so they’re not starting from a blank page.

Two things here caught my eye. First, notice who got handed the psilocybin study: the Office of Cannabis Management. States are increasingly treating cannabis and psychedelics as the same kind of regulatory expertise, which makes sense when you think about it. Both involve controlled substances, patient access, testing, licensing, and that same awkward standoff between state reform and federal law.

Second, and this is the part I find genuinely interesting, the model looks different from adult-use weed. Minnesota’s heading toward screening, supervised sessions, and qualifying conditions, not retail stores. And the framing has quietly shifted. The first wave of cannabis reform had to fight just to prove it was real medicine. Psychedelic policy is increasingly starting from the opposite assumption, that the clinical evidence is promising enough to deserve a pathway. With Trump’s executive order pushing faster access and Congress looking at veteran-focused proposals, the question in Minnesota isn’t really “should we” anymore. It’s “how.”

The bottom line: Minnesota is treating psychedelic therapy as an implementation problem, not a culture-war fight, and 2027 is shaping up to be the year something actually happens.

Share

A federal judge just said the quiet part out loud about weed and guns.

Judge Nicole Berner of the Fourth Circuit wrote a concurring opinion questioning whether an old legal assumption still holds up: the idea that where there are drugs, there are probably guns. That presumption lets police who suspect drugs during a traffic stop assume a firearm might be around too, which can justify a frisk. It’s built on decades-old logic.

Berner’s point is simple and hard to argue with. Cannabis is legal for medical or adult use in most states now. Millions of completely law-abiding adults have weed on them with zero connection to violence or trafficking. So treating the smell of cannabis as a reason to suspect someone’s armed basically strips Fourth Amendment protections from a giant group of ordinary people.

This connects to something bigger. Remember the recent Supreme Court ruling that weed use alone doesn’t justify taking away someone’s gun rights without actual evidence they’re dangerous? Same underlying shift. For decades, suspected possession was the skeleton key. It opened the door to searches, arrests, the whole cascade. As legalization spreads, that assumption drifts further and further from how people actually live.

Worth being clear on one thing: the court didn’t overturn the old precedent here. The judges were bound by existing circuit law and upheld the conviction. But Berner’s concurrence is a flare sent up to future courts, basically saying these prohibition-era doctrines are due for a hard look. And this one lands close to home for a lot of you, because the Fourth Circuit covers Maryland, Virginia, West Virginia, and the Carolinas.

The bottom line: As legalization spreads, courts are getting less comfortable treating a whiff of cannabis as automatic evidence of guns or danger. The old logic is wearing thin.

Share Hypotenews

Someone just turned hemp seltzer into a China story, and that’s a smart, dangerous move.

Former acting Homeland Security Secretary Chad Wolf is pushing Congress to keep the coming federal ban on many hemp THC products, and he’s not arguing about potency or packaging. He’s arguing national security. Wolf claims Chinese-linked actors and foreign criminal groups are tied up in the production and distribution of intoxicating hemp products and illegal grows, and he wants the House committee on competition with China to dig in.

I want to flag how big a shift this is, because it’s easy to miss. Until now the hemp fight has been about the normal stuff: age limits, testing, whether the 2018 Farm Bill accidentally legalized intoxicating cannabinoids. Wolf is yanking the whole conversation onto national-security turf, and that’s strategically powerful. Lawmakers who’d happily support a regulated hemp market get real nervous real fast once you attach words like “foreign criminal networks” and “Chinese influence.” The framing changes the incentives.

Here’s the sleight of hand to watch for, though. He’s blending two genuinely separate problems. Are there illegal grows and organized crime worth investigating and prosecuting? Absolutely, go get them. But that is not the same thing as saying every domestic hemp beverage, every CBD product, every low-dose edible should be federally wiped out. The ban set for November 12 would redefine legal hemp so tightly that only products with no more than 0.4mg of total THC per container survive, which the industry says takes out a huge chunk of full-spectrum CBD too, not just the intoxicating stuff. The White House and a bipartisan group have been pushing to slow this down and regulate instead. Wolf’s basically arguing that regulating rather than banning helps foreign actors, which is a neat way to make caution sound unpatriotic. The real task is separating actual security concerns from a blanket prohibition that mostly kills compliant American businesses.

The bottom line: The hemp fight just leveled up from consumer safety to national security. That framing is powerful, and it’s being used to defend a ban far broader than the actual problem.

A congressman brought back “loser in life,” and it tells you where the losing side is headed.

Rep. Pete Sessions said cannabis use can make someone a “loser in life,” damage your DNA, and put young women at greater risk of harm. He said this on a podcast produced by Smart Approaches to Marijuana, one of the big prohibition groups. He also claimed weed has no positive effects at all, which is a striking thing to say while nearly every state runs a medical marijuana program and the federal government is actively moving to recognize its medical value.

I’m not going to spend much time dunking on the DNA claim. What’s actually interesting is the gap it reveals. Cannabis today gets discussed by doctors, scientists, bankers, judges, and veterans’ groups as a real subject with measurable benefits and real risks. Sessions is reaching back to the moral language of a totally different era, where users are failures and one puff sets you on the road to ruin.

Now, I want to be fair here, because the antidote to bad arguments isn’t more bad arguments. Cannabis is not risk-free. Heavy use, teen exposure, driving impaired, and certain mental-health vulnerabilities all deserve to be taken seriously. But the actual cannabis consumer base is veterans, parents, executives, retirees, and patients, and most of them use occasionally without their lives falling apart. The reason Sessions matters isn’t the rhetoric itself. It’s that he’s supported drug testing for transportation workers and once used his perch on the Rules Committee to block cannabis amendments from even getting a vote. So this worldview shapes actual legislation. And honestly, the fear-based language getting louder is a tell. When the scientific and political ground is shifting under you, stigma is what you reach for.

The bottom line: The debate keeps getting more evidence-based, and some opponents are responding by leaning harder into fear and stigma. That’s usually what losing sounds like.

Massachusetts legalization might come down to 122 signatures.

The rollback measure in Massachusetts qualified for the November ballot, but reform advocates are challenging whether enough of the signatures were actually valid. And the margin here is wild. Organizers needed 12,429 signatures in the second round. Officials approved 12,551. That’s a cushion of 122. The challenge alleges some signatures were fake, gathered through misleading tactics, or came from people who weren’t properly registered, so even a small number tossed out could knock the whole thing off the ballot.

There’s a detail here that’s almost too on the nose: a campaign worker was reportedly let go after appearing to tell reform supporters to sign the repeal petition so voters could defeat it later. Organizers said that wasn’t acceptable and didn’t reflect their campaign. Whatever the commission ultimately decides, the fragility of the whole thing is the story.

But zoom out, because this is the part operators need to sit with. The measure would repeal commercial sales and home grow while keeping possession and medical. Think about how incoherent that is. You’d be legally allowed to have weed but stripped of any legal way to buy it. Licensed businesses face extinction. Towns lose the tax money. People lose jobs. And consumers just drift to the illicit market or across state lines. Massachusetts legalized back in 2016 and built a mature market, and now that whole industry might have to fight for its life over a rounding error’s worth of signatures.

The bottom line: Massachusetts legalization could hinge on a few disputed signatures, which is a brutal reminder that winning legalization once doesn’t mean it stays won.

A small study on restless legs points to where medical cannabis is actually heading.

Researchers looked at a cannabis formulation with roughly 2.7mg THC and 2.5mg CBD in patients with multiple sclerosis and idiopathic restless legs syndrome. Symptom severity dropped at one and three months, and among the people who stuck with it for a year, 67% held onto the improvement.

I’ll be upfront about the limits, because it matters. This was 18 people, and it was exploratory, not a big randomized trial. So hold it loosely. It’s a signal, not a verdict.

That said, here’s why it’s worth your attention. Restless legs syndrome isn’t a qualifying condition for medical cannabis in most states, and the usual treatments are things like dopamine agonists and gabapentinoids. Researchers got curious because cannabinoids may hit some of the same neurological pathways. And this fits a broader pattern I keep noticing: cannabis research is finally pushing past the greatest-hits conditions like cancer, epilepsy, and chronic pain into sleep disorders, movement disorders, and specific symptom clusters.

The commercial angle is the interesting twist. Look at that formulation again, low dose, balanced THC and CBD. That’s almost the opposite of the sky-high-THC products crowding most dispensary menus. If this is where medicine is going, the market may gradually shift toward condition-specific, precisely dosed products rather than just “what’s the strongest thing you’ve got.” And it makes a real case for letting doctors use judgment instead of locking them into a rigid list of qualifying conditions, because a fixed list always lags years behind the research. States that trust clinicians to recommend based on evidence will simply move faster.

The bottom line: Early days, but cannabis may open a new path for restless legs, and it shows why rigid qualifying-condition lists can’t keep up with the science.

Massachusetts, part two: the rollback is officially on the ballot, and it’s a test for the whole industry.

To be clear on where this landed: state officials certified that the Coalition for a Healthy Massachusetts got enough signatures, so barring the challenge above, voters decide in November whether to tear down the regulated recreational market. The measure repeals commercial sales and home grow while keeping possession and medical intact.

I covered the mechanics up top, so let me use this space for the bigger point, because it’s one every operator should internalize. This wouldn’t bring back old-school prohibition. It’d create something arguably dumber: legal to possess, illegal to buy anywhere legitimate. Possession stays, licensed retailers vanish, tax revenue evaporates, regulators lose all oversight of testing and labeling, and the illicit market basically gets handed the keys.

Now, the rollback supporters do have a fair democratic argument, that voters deserve to reconsider a system after nearly a decade of living with it. I don’t think that’s illegitimate, and pretending otherwise would be a mistake. But here’s what the industry has to absorb. Legalization is not a trophy you win once and put on a shelf. Mature markets have to keep proving, over and over, that regulation beats prohibition. That means actually dealing with the stuff people complain about: high prices, local bans, social equity that hasn’t delivered, youth prevention, impaired driving. The reform coalition of businesses and health professionals fighting this will lean on jobs, tax revenue, patient continuity, and that possession-without-sales contradiction. They’ll probably win. But the fact that they have to fight at all is the lesson.

The bottom line: Massachusetts is the first real test of whether voters who legalized weed will show up to defend it years later. Nobody should assume they will automatically.

Final thought

Cannabis policy isn’t being decided by one big legalization campaign anymore. It’s being built piece by piece through hospital studies, court decisions, clinical trials, agency records, signature disputes, and a running argument about what’s actually risky and what’s just old fear in a new suit.

That makes all of this harder to follow. It also raises the stakes. The future belongs to whoever can tell the difference between evidence and assumption, between real public-health concerns and political theater dressed up to look like concern.

Cannabis already won the culture. People stopped clutching their pearls years ago. The record is the part that’s still up for grabs, and that’s the fight that actually decides what the next decade looks like.

That’s what this newsletter is for.

What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.

If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.

Subscribe now

Cannabis reform isn’t about legalization anymore. It’s about rights, housing, hemp, and who quietly gets priced out of the legal future.

Here’s the thing nobody warns you about when you win: the hard part starts after.

“Legalize it” was the easy sell. Now comes the messy question of what happens next, and it turns out that question doesn’t get answered in one big federal moment. It gets answered in a hundred small decisions that most people never notice. That’s exactly what this week looked like.

Texas is threatening to burn down its own hemp market. A guy’s marijuana conviction from 1994 is somehow a Second Amendment case now. Virginia patients are being told to pick between their medicine and a roof over their heads. And the federal government, I promise I’m not making this up, published a report about scales.

None of it is flashy. All of it matters. Let me walk you through it.

Share

Texas is about to learn a hard lesson about banning things people already buy.

State Senator Charles Perry says he’s coming back to ban consumable hemp THC products. This follows a committee hearing that was basically a parade of warnings about youth use, mental health, and poison control calls. Perry talked up licensing fees high enough to push businesses out, and said he’s hit his breaking point with the hemp industry.

So here’s the situation Texas has gotten itself into. It has a huge hemp market and no legal weed. When the state didn’t build an adult-use system, hemp THC just quietly filled the gap, because that’s what happens when there’s demand and no legal way to meet it. Now lawmakers want to slam that gap shut without putting anything in its place.

You can probably guess how that goes. People who want THC don’t stop wanting it because a bill passed. They just buy it somewhere with no testing, no labels, and nobody checking IDs. Texas actually did the smart thing earlier this year with packaging rules, testing, and age limits. That’s regulation, and it works. What Perry’s describing isn’t tougher regulation, it’s demolition. And the market doesn’t disappear when you demolish the legal version of it. It just goes underground.

The bottom line: Texas isn’t really deciding how to regulate hemp. It’s deciding whether it can wish away a market that already exists, and that bet loses almost every time.

A weed conviction from 1994 just became a constitutional problem

An Air Force veteran is suing Pennsylvania over a law that permanently blocks anyone with a past drug conviction, including ancient marijuana possession, from getting a license to carry a firearm. His conviction was for a small amount of cannabis in 1994. No drug use since. No other record. Still permanently locked out.

The lawsuit points straight at the Supreme Court’s recent cannabis gun-rights ruling, arguing there’s just no historical basis for stripping someone’s gun rights forever over a nonviolent weed offense from three decades ago.

This is the part of reform people forget about. We spent so long arguing about whether cannabis should be legal that we skipped past a quieter question: what do we do about everyone still carrying the weight of old convictions? This guy lived cleanly for thirty-two years and still gets treated like a risk, all while the federal government is busy rescheduling the exact substance he was convicted for. That contradiction can’t hold forever, and cases like this are how it starts to fall apart. Legalization was step one. Undoing the damage from the prohibition years is step two, and we’re only just getting there.

The bottom line: Reform is moving past legalization into cleaning up old records, and those decades-old convictions are getting really hard to justify.

Virginia is making patients choose between their medicine and their housing.

There’s a sharp op-ed out arguing that Virginia’s state-certified recovery residences are being forced to ban all cannabis, medical included, under certification rules tied to Senate Bill 270. So if you’re a patient living in recovery housing, your options are to stop using medicine your doctor recommended, or risk losing the stable housing you need.

Think about how backwards that is. Virginia already protects medical cannabis patients from discrimination in hospitals, nursing homes, and schools. But recovery housing somehow gets carved out, so the same person with PTSD or chronic pain can legally use their medicine in one place and get kicked out for it in another. There’s no logic to it. It’s just an old bias that legalization didn’t automatically sweep away.

The op-ed floats an interesting legal angle too, that since medical cannabis is Schedule III now, denying someone housing over a doctor-approved, non-smoked medication might run afoul of fair housing and disability law. We’ll see if that holds up. But honestly, you don’t need the legal theory to see the problem. Medicine that can cost you your home isn’t really accessible. Legalization takes away the criminal penalty, sure. It doesn’t automatically fix all the other rules, housing, jobs, insurance, that still quietly treat cannabis like it’s disqualifying.

The bottom line: If using your medicine can cost you your housing, you don’t actually have access. Half-finished reform leaves these traps lying around everywhere.

Share Hypotenews

Illinois just quietly showed everyone what a grown-up cannabis market looks like.

Illinois regulators put out guidance on a new omnibus law, and the list of changes is telling: doubled possession limits, drive-thru and curbside pickup, longer hours with local sign-off, permission to hire their own security instead of being forced to use outside firms, and shorter surveillance retention.

Looks like housekeeping. It’s actually a big deal.

What you’re watching is Illinois graduate from “is this legal” to “how do we make this run well.” For years, operators dealt with rules that basically assumed they were up to something, mandatory third-party security, three months of surveillance footage, tight hours. Illinois is loosening that grip while keeping the market regulated, which is a real vote of confidence. Everyone’s going to talk about drive-thru weed, and fine, that’s fun. But the security changes are the actual story. Letting dispensaries run their own security and cut footage retention from 90 days to 60 says regulators have stopped treating them like suspects. That shift in attitude matters way more than the convenience stuff.

The bottom line: Illinois is moving from legalization to just making the market work better. That quiet move from suspicion to trust is what maturity really looks like.

The most boring story this week is secretly one of the most important.

The National Institute of Standards and Technology put out a report to help states set standards for the scales used to weigh marijuana. Accuracy classes, verification intervals, minimum loads, all of it. Cannabis is tricky, the report notes, because it’s expensive, moisture-sensitive, and sold in tiny amounts.

I know. Scales. Hang with me for a second, because this matters more than it sounds.

Every legit market runs on trust. You need to know you got what you paid for, regulators need consistency, and businesses need rules that are precise without being ridiculous. Weights and measures are the foundation of all of it. It’s the same reason it never crosses your mind that the gas pump might be shorting you. Somebody set that standard a long time ago and now you just trust it.

The fact that federal agencies are now fussing over scale intervals for cannabis is actually a sign the industry made it. The early years were all about the giant philosophical fights. This is what comes after, the unglamorous plumbing that turns a gray market into a real one. The boring stuff isn’t a distraction from legitimacy. It’s how legitimacy gets built.

The bottom line: Normalization now includes the boring machinery of commerce, and that boring machinery is exactly what makes people trust a regulated market.

THC drinks are quietly stealing customers from alcohol.

A new Crescent Canna survey found that more than three out of four THC beverage drinkers cut back on alcohol after making the switch. 37% drink much less, and 21% quit booze entirely. Almost half say the drinks are part of a regular wellness routine, and 60% point to the lack of a hangover as the big draw.

I’ve said before that hemp beverages are the most interesting growth story in cannabis, and this is why. These drinks aren’t just another product on the shelf. They’re a straight-up alcohol replacement, and that’s a much bigger deal. They’re social, easy to dose, and familiar to people who would never smoke or walk into a dispensary. That’s the crowd cannabis has always had trouble reaching, and beverages get there without even trying.

But there’s a catch hanging over the whole thing, and it’s that November hemp cliff. The survey found people already know restrictions might be coming, and some are stocking up. If hemp THC drinks get banned without a legal path forward, a bunch of these folks go right back to alcohol. Really sit with that for a second. Here’s a product measurably helping adults drink less, and clumsy policy could shove them back toward the thing that’s worse for them. Whoever’s writing these hemp rules might be badly missing what this category has quietly become.

The bottom line: THC drinks have gone from novelty to genuine alcohol alternative, and a sloppy hemp ban could hand all those customers straight back to booze.

Leave a comment

Oregon is about to price its own psilocybin experiment out of business.

Oregon regulators want to jack up fees across the psilocybin industry, doubling annual manufacturer and service-center licenses from $10,000 to $20,000. The program pays for itself through fees instead of tax dollars, and the money isn’t keeping up with costs.

The budget math is real. The fallout could be brutal.

This is the clearest warning in this whole edition, and it points right at cannabis. Oregon built the first legal psilocybin program in the country as a mental health breakthrough. But sessions already run $850 to $3,000, so access has skewed heavily toward people with money. Now higher fees mean more closures and even steeper prices. And here’s the kicker: about half the licensed service centers have already expired or been handed back. The thing was wobbling before anyone floated a fee hike.

That’s not just businesses struggling. It’s an access problem, and it’s the exact trap cannabis keeps flirting with. A market can technically be legal while fees and taxes and compliance costs make it impossible for anyone but the deep-pocketed to actually play. Legal on paper, out of reach in practice. Oregon’s running that experiment live right now, and it’s not looking good.

The bottom line: Oregon might end up proving that legal-but-unaffordable is just prohibition wearing a nicer suit. Access nobody can actually use isn’t really access.

Virginia’s writing the rulebook now, and the rulebook is where everything gets decided.

The Virginia Cannabis Control Authority opened a public survey, running through July 21, to collect input as it drafts adult-use rules on licensing, fees, security, advertising, testing, packaging, enforcement, and the rest.

This is where the real work of legalization actually happens, and it’s the part almost nobody pays attention to. Passing the law was the headline moment. But a law just says a market is allowed. It doesn’t build one. Every question that decides who actually wins and loses gets settled right here, in the rulemaking. Who gets licenses. How fees are set. Whether the testing rules are realistic. Whether a small operator or an equity applicant can even afford to get in the door.

Remember that $10 million conversion fee for medical operators from Virginia’s legalization deal? That’s precisely the kind of quiet detail that tilts a whole market toward the big multi-state players and away from local businesses. The survey’s genuinely a good move, and asking patients, small operators, and health experts what they think is the right instinct. But asking only counts if they actually listen. The real test isn’t whether Virginia sends out a survey. It’s whether it pays attention before the rules lock in, because once they harden, they’re a nightmare to undo.

The bottom line: Virginia is moving from headline to rulebook, and it’s the rulebook, not the law, that decides who really benefits.

Final thought

Cannabis reform has stopped waiting on one big breakthrough, and this week is the proof that it’s not coming.

Instead the industry is getting built, and sometimes broken, through a thousand smaller calls. Who keeps their housing. Who can carry a gun. Who’s allowed to sell hemp. Who can afford psilocybin therapy. How dispensaries run. How product gets weighed. Who writes the rules for the next market.

None of it fits on a protest sign. All of it decides who actually makes it in the legal industry that reform created.

This is the fine print era. And in cannabis, the fine print is the fight now.

That’s what this newsletter is for.

What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.

If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.

Subscribe now

Look at the spread of fights this week. A state Senate is being pressured to simply allow a vote. The DEA and FDA stood up in a federal hearing and admitted cannabis is safer than alcohol and opioids — reversing decades of their own messaging. A study found cannabis nearly eliminated opioid use in chronic pain patients. The Supreme Court’s gun ruling is already rippling into other cases. And Virginia finally — finally — legalized actual sales.

This is the institutional phase. It’s harder to follow than the legalization era, and far more consequential. Here’s what happened, and what I actually think it means.

Pennsylvania’s fight isn’t about support anymore. It’s about whether leadership will allow democracy to function.

Every Democratic senator in Pennsylvania is backing a discharge resolution to force a bipartisan legalization bill out of committee and onto the floor. The bill has bipartisan sponsorship, the governor’s support, and 75% public approval — and it’s still stuck.

That’s the part worth sitting with. This isn’t a question of whether cannabis has support in Pennsylvania. It obviously does. It’s a question of whether Senate leadership will let the chamber vote on something most of the state already wants.

My read: Pennsylvania has stopped deciding whether cannabis should exist and started deciding whether it wants to regulate and tax a market that already exists all around it. Every day the bill sits in committee, Pennsylvania consumers drive across the border and hand their money — and the tax revenue attached to it — to New Jersey, Maryland, and New York. That’s not a moral stance against cannabis. It’s just leaving money on the table while pretending the market isn’t there. The procedural blockade is the whole story now.

The bottom line: Pennsylvania’s cannabis fight is no longer about public opinion. It’s about whether Senate leadership will let democracy move.

Subscribe now

The opioid-displacement study is the most important medical cannabis data in a while.

Researchers studied 241 patients with treatment-resistant lower back pain and found inhaled cannabis produced large, sustained improvements — and near-total displacement of opioids, NSAIDs, antidepressants, and gabapentinoids.

I want to be careful not to overstate this — it’s one study, and cannabis isn’t a universal cure. But the finding matters enormously, and here’s why: lower back pain is one of the most common, costly, and opioid-entangled conditions in the world. Any intervention that reliably reduces opioid reliance in this population isn’t a wellness story. It’s a public-health story.

My read: this is where the medical cannabis conversation is finally maturing. For years the industry talked about THC percentage like it was the only variable that mattered. This study focused on delivery method — inhaled, for rapid onset and easier dose control — because that’s what actually drives patient outcomes. The sophisticated future of medical cannabis is in formulation, onset, consistency, and real-world results, not potency bragging rights. And the opioid angle reframes the entire policy debate: if cannabis can pull chronic-pain patients off opioids, medical access stops being a lifestyle question and becomes part of the overdose-crisis response.

The bottom line: Medical cannabis is increasingly judged by outcomes, not ideology — and the opioid-displacement data is getting very hard to dismiss.

Share

The DEA and FDA just dismantled their own decades-old argument — on the record.

The rescheduling hearing opened with DEA and FDA officials highlighting cannabis’s medical benefits and its relative safety compared to alcohol and opioids, with the government acting as the formal proponent of moving cannabis to Schedule III.

Stop and appreciate how remarkable this is. Schedule I status rested entirely on two claims: no accepted medical use, and high abuse potential. This week, federal officials stood in an official proceeding and began building a record that says the opposite — that cannabis has medical value and comparatively lower harms.

My read: this is the single clearest signal yet that the old federal narrative is collapsing under its own weight. You cannot spend decades arguing cannabis has “no accepted medical use” and then have your own agencies testify to its medical benefits without fundamentally undermining the original position. That contradiction doesn’t just affect rescheduling — it weakens the government’s footing in every other cannabis fight, from the gun-rights cases to 280E.

But hold the celebration. The DEA still invited only reform opponents as formal participants, and still refuses to livestream. So we have a genuinely historic record being built inside a process designed to look one-sided. Both things are true at once.

The bottom line: The government is no longer defending the Schedule I narrative with any confidence. That’s historic — even inside a flawed process.

Idaho proves you can win the public and still lose to the process.

Idaho’s medical cannabis ballot campaign collected a large pile of signatures — and then hit the procedural wall. One county tossed roughly 4,000 signatures as late, and the campaign now faces uncertainty over residency verification and Idaho’s brutal district-level distribution requirement: 6% of registered voters in at least 18 of 35 legislative districts.

That district rule is the killer, and it deserves attention. A campaign can gather a massive raw signature total and still fail if those signatures aren’t spread correctly across the map.

My read: this is the under-discussed reality of cannabis reform in prohibitionist states. We talk about reform like it’s a persuasion problem — convince enough people and you win. But in states like Idaho, it’s an election-law problem: deadlines, county verification, paid circulators, distribution thresholds, and litigation. Ballot initiatives are often the only realistic path to reform in conservative states, and those paths are being deliberately narrowed by procedural barriers. Public momentum is necessary but nowhere near sufficient.

The bottom line: Idaho shows cannabis reform can have real public support and still get blocked by process. In prohibitionist states, the rules of the game matter as much as the votes.

Leave a comment

Virginia finally ended its contradiction — and immediately created a new one.

Virginia did it. Lawmakers approved a budget package legalizing recreational sales, ending the bizarre limbo where adults could possess and grow cannabis since 2021 but had nowhere legal to buy it. Sales begin July 1, 2027 — up to two ounces per transaction, up to 350 licensed retailers, delivery allowed, and existing medical operators able to convert for a $10 million fee.

For the DMV region, this is a genuine shift — it reshapes the competitive map with Maryland and D.C., plus real estate, licensing, and tax dynamics across the region.

My read: this is a real victory, and I don’t want to undercut it. But the same bill raises the public-use fine from $25 to $250 — and as I covered last week, FOIA data shows public-use enforcement has already fallen disproportionately on Black Virginians since 2021. So Virginia resolved one contradiction (legal to possess, illegal to buy) and built another one (a legal market that preserves an enforcement tool with documented racial disparities). That $10 million conversion fee is also worth watching — it’s a number that quietly favors well-capitalized multi-state operators over smaller local players, which shapes who actually gets to participate in this market.

The bottom line: Virginia moved from limbo to legal commerce — but the fine structure and fee design will determine whether this market is actually fair.

The gun-rights ruling is already spreading — exactly as predicted.

The Supreme Court’s ruling protecting a cannabis consumer’s gun rights is already being applied to other cases, weakening the federal government’s blanket position that marijuana use automatically makes someone too dangerous to own a firearm.

I flagged this when the ruling first landed, and it’s playing out faster than expected. The key principle is individualized risk: the government can still regulate firearm possession by people who actually pose danger, but cannabis use alone is becoming a much weaker basis for automatic disqualification.

My read: this is cannabis doing what it keeps doing — exposing the federal government’s internal contradictions and forcing courts to resolve them. You can’t move toward recognizing cannabis’s medical value through rescheduling while simultaneously treating every medical cannabis patient as a categorically prohibited person. Courts have noticed, and now precedent is compounding. For patients specifically, this matters enormously: nobody using state-legal medicine should have to choose between symptom relief and a constitutional right. That forced choice is finally cracking.

The bottom line: Cannabis is colliding with constitutional law, and the broad federal assumptions about marijuana users are breaking down case by case.

The 280E tax fight exposes a genuine political contradiction.

A new op-ed targets Republican efforts to preserve punitive cannabis tax treatment under Section 280E — the rule barring businesses that traffic Schedule I or II substances from deducting ordinary expenses. If cannabis moves to Schedule III, 280E stops applying the same way, letting operators finally deduct rent, payroll, security, and marketing.

My read: I keep saying 280E matters more than most legalization headlines, and this is why. For many operators, the ability to deduct normal business expenses is literally the difference between survival and collapse. It distorts the entire market — compliant operators carry an effective tax rate that illicit sellers, who pay nothing, simply don’t.

The political contradiction the op-ed identifies is real and worth naming: some of the same lawmakers who campaign on lower taxes and supporting small business are working to preserve one of the harshest tax regimes imposed on any legal American industry. I try to keep this newsletter from being partisan, so I’ll put it neutrally — there’s a genuine tension between a stated philosophy of low taxes and pro-business policy, and an active effort to maintain 280E’s burden on legal operators. Readers can judge that tension for themselves. But operators should understand the stakes: rescheduling may be the single largest tax event in cannabis history.

The bottom line: Rescheduling isn’t just drug policy. It may be the biggest tax event the industry has ever seen — and there’s real political resistance to letting it happen.

The activists outside DEA headquarters are making the right argument.

Cannabis reform activists protested outside DEA headquarters over their exclusion from the rescheduling hearing — which features only legalization opponents as formal parties, with no livestream for the public.

I’ve covered the access problem the past two weeks, but the activists are sharpening the framing in a useful way: this isn’t only about the final rule. It’s about the record that gets built along the way.

My read: the procedural questions sound boring, and that’s exactly why they’re dangerous to ignore. Who testifies? Who cross-examines? Who counts as an “interested person”? Who gets excluded? Those technical choices shape the evidentiary record — and that record is what courts will lean on for years when the inevitable legal challenges come. The opposition understands that building the record is half the battle. The reform movement is, belatedly, realizing it too. Federal reform isn’t won by public-opinion polls or state legalization maps. It’s won through administrative law and procedural legitimacy — terrain the industry has historically underinvested in.

The bottom line: The rescheduling fight is now a fight over the record itself — and reformers are right not to let opponents define it alone.

Final thought

The cannabis industry has stopped waiting for one clean legalization moment to arrive. It isn’t coming.

Instead, the industry is being shaped by eight systems at once: state legislatures, courts, ballot campaigns, federal agencies, tax law, medical research, public opinion, and administrative hearings. All moving at different speeds, sometimes in opposite directions.

That makes this era genuinely harder to follow than the activist days. A single ballot-night victory is easy to understand. A discharge resolution, a 280E deduction fight, a signature-distribution requirement, and an administrative hearing record are not.

But that complexity is the whole point. This is what an industry looks like once it’s real — woven into every institution, forcing each one to take a position.

The next winners won’t just understand cannabis. They’ll understand government.

That’s what this newsletter is for.

What’s the biggest regulatory challenge your operation is facing right now? Hit reply — I read every response and it shapes what I cover next week.

If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.

Subscribe now

Read more

The next winners in cannabis won’t be the loudest. They’ll be the most prepared.

Read more

For twenty years, cannabis reform followed a predictable script: legalization campaigns, ballot initiatives, state legislation, public opinion. Win hearts, win votes, win markets.

That script is being torn up.

The biggest cannabis stories this week aren’t about new states legalizing or new markets opening. They’re ab…

Read more

This week, the White House quietly signaled that the crackdown isn’t coming — at least not the version everyone feared.

That single shift tells you almost everything about where cannabis policy is heading in 2026. The fight is…

Read more

Progress and regression are happening simultaneously.

This week, the WNBA removed cannabis from its banned substances list — a genuine cultural milestone. At the same moment, congressional amendments designed to protect hemp-derived THC products were blocked, a lawsuit was filed against federal rescheduling, and Virginia’s governor vetoed a bill that would have finally opened retail sales in a state where cannabis is already technically legal.

That’s the cannabis industry in 2026. Two steps forward, one step sideways, one step into a courtroom.

The operators who thrive in this environment won’t be the ones waiting for clarity to arrive. They’ll be the ones building their businesses to function without it.

Here’s what happened this week — and what I actually think it means.

Share

The WNBA just made a bigger statement than most politicians have.

The WNBA officially removed cannabis from its banned substances list this week, while simultaneously establishing guidelines for player endorsements with cannabis companies.

Let’s be clear about what this actually is: a major professional sports league looked at cannabis and decided it belongs in the same category as alcohol and caffeine, not steroids and amphetamines. That’s not a small thing.

Professional sports leagues have historically been among the last institutions to update their cannabis policies — for obvious reasons, sponsors, federal relationships, image concerns. The fact that the WNBA moved here, and moved decisively, reflects something real about where mainstream America has landed on this issue.

The endorsement piece may end up mattering even more than the policy change. Athletes carry consumer trust in a way that brands spend millions trying to manufacture. Cannabis companies that build authentic relationships with WNBA players now are making a long-term bet that will look smart in five years.

The bottom line: When professional sports leagues start treating cannabis like a normal consumer product, the cultural argument is over. We’re there.

Share Hypotenews

Hemp’s worst week in years — and it’s not over.

Congressional amendments designed to protect hemp-derived THC products — Delta-8, THCA flower, hemp beverages, alternative cannabinoids — were blocked from advancing this week.

I want to be direct about how serious this is. The hemp-derived cannabinoid market has grown into a multi-billion dollar industry operating in a regulatory gray zone that Congress created, largely by accident, with the 2018 Farm Bill. That gray zone is closing.

The arguments on both sides are real. Hemp operators argue they’re driving innovation and expanding consumer access to cannabinoids that help people. Licensed cannabis operators argue they’re competing against businesses that don’t pay their taxes, don’t carry their licensing costs, and don’t play by the same compliance rules. Both are telling the truth.

But here’s what I think actually happens: Congress will pass something restrictive, it will be written poorly, it will disproportionately hurt smaller operators who can’t afford the legal firepower to navigate new requirements, and the big players on both sides will be fine. That’s how these things tend to go.

If you’re in the hemp space and you’ve been hoping this problem goes away on its own — it won’t. The window to build your compliance infrastructure before the rules land is shorter than you think.

The bottom line: The hemp THC fight may be the single most consequential cannabis policy battle of 2026. Treat it that way.

Leave a comment

Virginia is still Virginia.

After Governor Abigail Spanberger vetoed legislation to legalize adult-use retail sales, Virginia lawmakers are now exploring whether they can attach legalization provisions to budget legislation to get around the veto.

I’ve written about Virginia before and my view hasn’t changed: this state is the clearest possible example of the gap between legalizing cannabis and building a cannabis market. Residents can possess it. They can grow it at home. They just can’t buy it from a regulated retailer. That’s not a cannabis policy — it’s a contradiction.

The budget legislation route is creative, and it might work. But it’s also a sign of how politically complicated this has become. When you’re trying to pass cannabis legalization through budget amendments, you’ve moved well past simple policy disagreement into something messier.

The deeper issue is that every state watching Virginia is learning the same lesson: the political coalition that passes legalization is not always the same coalition that builds a functional market. Those are two different fights, requiring two different strategies.

The bottom line: Virginia will get there. But the timeline keeps moving, and the lesson for other states is getting clearer: plan your implementation before you pass your bill, not after.

Someone sued Trump over rescheduling. Here’s why it matters.

A coalition of physicians, substance abuse professionals, and cannabis pharmaceutical interests filed a lawsuit this week challenging federal marijuana rescheduling efforts.

The political coalition behind this lawsuit is worth paying attention to. It’s not prohibitionists arguing cannabis is dangerous. It’s a mix of medical professionals with genuine concerns about the research process and pharmaceutical interests who have financial stakes in keeping cannabis in a regulatory category they can control. Those are very different motivations dressed up in the same lawsuit.

What this tells me is that the opponents of reform have largely abandoned the public opinion battlefield — they’ve lost it — and are now fighting on administrative and legal terrain. That’s a slower game, but it can be effective. Federal administrative law is complicated, courts move slowly, and a successful legal challenge could delay rescheduling by years.

Operators should not assume rescheduling is a done deal. I’m not saying it fails — I think it eventually succeeds — but the path runs through federal courts now, not just agency rulemaking, and that adds meaningful uncertainty to the timeline.

The bottom line: The next major cannabis battles will be won and lost inside courtrooms. If you don’t have someone on your team who understands federal administrative law, you have a gap.

Wisconsin is the next big domino — and candidates know it.

Democratic gubernatorial candidates in Wisconsin pledged this week to support cannabis legalization, hemp protections, and additional executive actions if elected.

Wisconsin is one of the largest remaining states without adult-use legalization, and it sits surrounded by states that have moved. Illinois is generating over a billion dollars a year in cannabis tax revenue directly across the border. That’s not an abstract policy argument — that’s money Wisconsin is watching leave.

The political dynamics are shifting. When Republican-leaning rural voters start connecting cannabis legalization to farm income (hemp) and tax revenue (adult-use), the partisan math changes. Wisconsin is closer to moving than the headlines suggest.

The bottom line: Non-legalized states with legalized neighbors are running out of reasons to wait. Watch Wisconsin closely.

Share

California just complicated tribal cannabis — again.

California Attorney General Rob Bonta issued an opinion this week stating that tribes seeking to participate in statewide cannabis commerce must obtain state licenses — they cannot operate under tribal sovereignty alone.

This one is genuinely complicated, and I want to resist the urge to oversimplify it.

Tribal sovereignty is a serious legal principle with deep roots in federal law. The argument that tribes should be able to operate cannabis businesses outside state licensing frameworks isn’t frivolous — it’s grounded in legitimate legal theory. At the same time, California built its cannabis regulatory system on the premise that everyone operating in the state market plays by the same rules. Both of those things can be true simultaneously.

What this ruling really signals is that cannabis is now complex enough that it’s surfacing legal tensions that have existed for decades in other industries. The intersection of tribal law, federal law, and state cannabis regulation is going to generate litigation for years.

The bottom line: Jurisdictional and licensing complexity is only increasing. If your business touches multiple regulatory frameworks, you need counsel who understands all of them.

Republicans are fighting for hemp. That’s not a headline from five years ago.

Even after this week’s setbacks, Republican lawmakers are continuing to push for federal protections for the hemp-derived cannabinoid industry.

The political significance here shouldn’t be underestimated. Cannabis reform used to be a Democratic issue. Hemp protection is increasingly a Republican one — driven by agricultural districts, small business interests, and economic development concerns in rural states. That’s a genuine realignment.

When Republican legislators from conservative states are fighting to protect hemp THC products, the “cannabis is a liberal issue” framing is finished. This is now an economic issue with a broad bipartisan constituency, which means it will eventually get addressed by Congress — the question is just whether the result helps or hurts current operators.

The bottom line: The bipartisan coalition forming around hemp is the most underreported political development in cannabis right now. Pay attention to it.

Read more

It finally has it.

And somehow, that’s made everything more confusing.

We’ve entered what I’m calling the Clarification Era — and I’d argue it’s going to be harder to navigate than the prohibition era was.

At least under prohibition, the rules were clear: cannabis was illega…

Read more

Legalization.

Today, it faces a much harder one:

Institutionalization.

The latest developments in the cannabis space paint a picture of an industry entering a new phase—one where the biggest threats and opportunities are no longer coming from activists or ballot initiatives, but from:

• Federal regulators

• St…

Read more

It is now colliding directly with the center of it.

Over the last 24 hours, the latest reporting from the industry reveals an industry rapidly entering its most consequential phase yet:

the federal implementation era.

That means:

• lawsuits,

• administrative hearings,

• polling wars,

• lab…

Read more

Today, it’s being absorbed into it.

The latest developments from last few days reveal a rapidly evolving landscape where marijuana is no longer treated solely as:

• a cultural issue,

• a criminal issue,

• or even just a state-level issue.

Cannabis is now becoming:

• a healthcare issue,

• a labor iss…

Read more

Now it’s fighting over structure.

Over the last 24 hours, the latest reporting shows a rapidly evolving industry where:

• governors are vetoing legalization frameworks while still supporting legalization itself,

• federal agencies are scrambling to clarify cannabis policies,

• lawmakers are attempting to regulate…

Read more

Now?

It’s inside:

• Congress

• Hospitals

• Federal agencies

• Veteran healthcare programs

• Corporate retail

• Scientific research institutions

And that changes everything.

Because once an industry becomes economically meaningful and politically unavoidable, the conversation stops being:

“Should this exist?”

And become…

Read more

That argument is mostly over.

Now comes the harder phase:

Who gets to regulate it, profit from it, restrict it, and define its future?

Today’s latest dev…

Read more

Cannabis enforcement is tightening.

Federal agencies are adapting to legalization.
Federal officials are still insisting marijuana remains illegal.

And somehow… all of those things are true at the same time.

Today’s latest developments from show an industry entering a deeply unstable—but incredibly important—transition phase.

…

Read more

Now that it has?

The resistance machine is activating.

Today’s latest developments from reveal a critical shift:

The conversation is no longer about whether reform happens.

It’s about:

• How far it goes

• Who controls implementation

• And whether opponents can slow it down through courts, Congress and r…

Read more

If you were expecting things to cool off after the federal shift… they didn’t.

They sped up.

What we’re seeing now isn’t just “post-rescheduling” news.
It’s the realignment phase:

• Washington is reframing the narrative

• States are tightening and expanding at the same time

• Hemp, cannabis and psychedelics are colliding into o…

Read more

• “Soon”

• “Under review”

• “Pending”

Yesterday, that changed.

Not in theory. Not in committee. Not in a leaked memo.

In action.

The federal government just made one of the most consequential cannabis policy moves in decades—reshaping research, taxation, and the future of the industry in a single stroke.

An…

Read more

• Protests

• Smoke circles

• A middle finger to the system

Today?

• Big-box retailers are selling THC drinks

• States are debating billion-dollar markets

• Federal agencies are still… “reviewing”

That’s the arc.

4/20 didn’t disappear. It scaled.

And now it sits at the center of a strange reality:

Cannabis is:

• Celebrated culturally

• Accepted economic…

Read more